Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print February 7, 2007, doi:10.1212/01.wnl.0000256768.79353.60)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000256768.79353.60v1
68/16/1284    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Illa, I.
Right arrow Articles by Gallardo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Illa, I.
Right arrow Articles by Gallardo, E.
Received March 28, 2006
Accepted December 11, 2006

Symptomatic dysferlin gene mutation carriers. Characterization of two cases

I. Illa MD, PhD*, N. De Luna BSc, R. Domínguez-Perles BSc, R. Rojas-García MD, C. Paradas MD, J. Palmer MD, C. Márquez MD, P. Gallano PhD, and E. Gallardo PhD

From Servei de Neurologia i Laboratori de Neurologia Experimental (I.I., N.D.L., R.D.-P., R.R.-G., E.G.), Servei de Radiologia (J.P.), Servei de Genètica (P.G.), Hospital de la Santa Creu i Sant Pau i Institut de Recerca de HSCSP, Universitat Autònoma, Barcelona, Spain; and Servicio de Neurología (C.P., C.M.), Hospital Universitario Valme, Sevilla, Spain.


* To whom correspondence should be addressed. E-mail: iilla{at}santpau.es.

Abstract-- Objective: To describe two symptomatic dysferlin gene mutation carriers. Methods: One patient had limb girdle weakness. His brother was diagnosed with limb girdle muscular dystrophy 2B with two mutations in the dysferlin gene (D625Y and E1734G). The second patient had distal weakness. He had two sons with Miyoshi myopathy with a homozygous mutation (G519R). We performed immunofluorescence (dystrophin, DAG proteins, dysferlin, caveolin-3), Western blot (dysferlin, caveolin-3, calpain-3), and real-time PCR (dysferlin) using skeletal muscle samples. We also studied dysferlin in peripheral blood monocytes (PBMs) by Western blot. Results: In addition to the muscle weakness, both patients showed elevated creatine kinase and abnormal muscle MRI. They presented a mutation in only one allele after screening of the whole gene (skeletal muscle and monocyte mRNA and genomic DNA). A muscle biopsy specimen showed moderate dystrophic changes and patchy dysferlin expression in the sarcolemma. Western blot of both PBMs and skeletal muscle demonstrated a significant reduction in dysferlin. All the other proteins including caveolin-3 and calpain-3 were normal. Real-time PCR showed normal levels of dysferlin mRNA vs the patients’ affected relatives. Conclusions: The diagnosis of symptomatic carriers of dysferlin mutations should be considered when a pathologic pattern of dysferlin protein is observed.




This article has been cited by other articles:


Home page
NeurologyHome page
A. A. Amato
ADULTS WITH EOSINOPHILIC MYOSITIS AND CALPAIN-3 MUTATIONS
Neurology, February 26, 2008; 70(9): 730 - 731.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.